Streetbeat News

Equity Actions

MRVI

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has announced the completion of its planned CEO succession, with William 'Trey' Martin, III assuming the role of CEO. Carl Hull, Maravai's co-founder and prior interim CEO, will continue to serve as the company's Executive Chairman. Martin has over 25 years of executive leadership experience in life sciences operations, engineering, sales, product development and marketing.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:50 pm

MITA

Harry You, the CEO and CFO of Coliseum Acquisition, has resigned from his positions effective July 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:49 pm

DPSI

DecisionPoint Systems, Inc. (NYSE:DPSI) has promoted Melinda Wohl to the position of Chief Financial Officer. Wohl, who has been with the company for nearly 20 years, was previously the Vice President of Finance and Administration. As CFO, she will continue to oversee financial planning, budget analysis, treasury management, M&A, and governance.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:44 pm

FSLR

First Solar, Inc. (NASDAQ:FSLR) reported Q2 earnings of $1.59 per share, beating the analyst consensus estimate of $0.96. The company also reported quarterly sales of $811.00 million, surpassing the analyst consensus estimate of $720.55 million. In addition, First Solar announced a $1.1 billion investment in a new US manufacturing facility.

Portfolio Pulse from Ryan Gustafson

July 27, 2023 | 8:41 pm

SSNC

SS&C Technologies Holdings, Inc. (SSNC) has provided its financial guidance for FY 2023. The company expects its EPS to be between $4.57 and $4.77, which is slightly lower than the estimated $4.78. The projected revenue is between $5.469 billion and $5.575 billion, which is in line with the estimated $5.53 billion. The company does not provide reconciliations of guidance for Adjusted Revenues and Adjusted Net Income to comparable GAAP measures due to the unpredictability of certain items such as acquisition transactions, foreign exchange rate changes, and other non-cash adjustments.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 8:38 pm

SSNC

SS&C has announced a $1 billion common stock repurchase program as part of its capital allocation strategy to maximize stockholder value. The repurchases may be made on the open market or in privately negotiated purchases, depending on market conditions and in accordance with applicable rules and regulations. The timing and amount of any shares repurchased will be determined by the company's management. The repurchase program may be suspended or discontinued at any time.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:36 pm

KDP

MDLZ

Mondelez International has sold its remaining investment in Keurig Dr Pepper, approximately 23 million shares, and received about $704 million in proceeds, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:33 pm

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has announced its intention to offer and sell shares of its common stock and warrants in a public offering. The size of the offering has not been disclosed. The proceeds will be used for working capital, general corporate purposes, and the build out of the company's manufacturing and R&D facilities. A.G.P./Alliance Global Partners and Brookline Capital Markets are acting as placement agents for the offering.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:33 pm

ENPH

Enphase Energy, Inc (NASDAQ:ENPH) reported Q2 earnings of $1.47 per share, beating the analyst consensus estimate of $1.25. However, its quarterly sales of $711.12 million missed the analyst consensus estimate of $722.12 million. The company expects Q3 revenue between $550 million and $600 million, lower than the $748.08 million estimate. The company also announced a new share repurchase program of up to $1.0 billion. Following the report, ENPH shares were down 13.4% in after-hours trading.

Portfolio Pulse from Ryan Gustafson

July 27, 2023 | 8:31 pm

PFE

Pfizer Inc has announced a restructuring of its Research and Development organization, with Oncology becoming a stand-alone unit. Chris Boshoff, currently Chief Development Officer - Oncology, will take on the role of Chief Oncology Research and Development Officer.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 8:25 pm